ABI-007

Phase 3Small molecule

Bristol-Myers Squibb

ABI-007 is one of 217 small molecule programs targeting Fallopian Tube Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

216

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fallopian Tube CarcinomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Bladder CancerActive, not recruiting

Gastric CancerActive, not recruiting

Fallopian Tube CarcinomaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

ABI-007

Bristol-Myers Squibb

Phase 3

9 2

Tykerb

GSK

Preclinical

80 3

Spravato

WWim Janssens

Preclinical

2 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 5

Avastin

Roche

Preclinical

4 6

Paracetamol

GSK

Preclinical

1 7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Perflutren Lipid Microcpheres

TThomas Jefferson University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer9 trials

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Completed·LLoyola University·Phase 2·NCT00654836·32 enrolled

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00046514·100 enrolled

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00394082·50 enrolled

Show 6 more trials

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00394251·197 enrolled

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00274456·302 enrolled

First Line Therapy for Patients With Metastatic Breast Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00456846·123 enrolled

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00140140·16 enrolled

Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00046527·460 enrolled

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00281528·208 enrolled

Metastatic Melanoma3 trials

Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00093119·75 enrolled

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01827111·21 enrolled

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

Completed·MMt. Sinai Medical Center, Miami·Phase 2·NCT00483301·34 enrolled

Pancreatic Cancer2 trials

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT01964534·114 enrolled

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02021500·40 enrolled

Refractory Solid Tumors1 trial

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01478685·169 enrolled

Advanced NSCLC1 trial

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00274443·250 enrolled

11 more indications

Metastatic Colorectal Cancer1 trial

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02103062·41 enrolled

Bladder Cancer1 trial

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00585689·29 enrolled

Non-Small Cell Lung Cancer1 trial

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00073723·75 enrolled

Vascular Access1 trial

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00249002·9 enrolled

Advanced Head and Neck Cancer1 trial

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

Completed·UUniversity Health Network, Toronto·Phase 1·NCT00731380·12 enrolled

Melanoma1 trial

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00864253·529 enrolled

Hematologic Malignancies1 trial

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00046423·20 enrolled

Gastric Cancer1 trial

Phase II Study of ABI-007 for Gastric Cancer

Completed· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 2·NCT00661167·56 enrolled

Fallopian Tube Carcinoma1 trial

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00407407·6 enrolled

Neoadjuvant1 trial

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)

Completed·EEmory University·Phase 2·NCT00503750·27 enrolled

Advanced Urothelial Cancer1 trial

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00995488·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for ABI-007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABI-007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABI-007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

ABI-007

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer9 trials

Metastatic Melanoma3 trials

Pancreatic Cancer2 trials

Refractory Solid Tumors1 trial

Advanced NSCLC1 trial

Metastatic Colorectal Cancer1 trial

Bladder Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Vascular Access1 trial

Advanced Head and Neck Cancer1 trial

Melanoma1 trial

Hematologic Malignancies1 trial

Gastric Cancer1 trial

Fallopian Tube Carcinoma1 trial

Neoadjuvant1 trial

Advanced Urothelial Cancer1 trial

References

Drug Info

Quick Facts

Related News